Cargando…

VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types—A Meta-Analysis

SIMPLE SUMMARY: The liver is a common site of metastasis across multiple solid organ malignancies. Liver metastases are a known site of treatment resistance, regardless of the site of primary tumour, and their presence is associated with a poor prognosis. This meta-analysis of 4445 patients from 25...

Descripción completa

Detalles Bibliográficos
Autores principales:	Conway, Jordan W., Braden, Jorja, Lo, Serigne N., Scolyer, Richard A., Carlino, Matteo S., Menzies, Alexander M., Long, Georgina V., da Silva, Ines Pires
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605052/ https://www.ncbi.nlm.nih.gov/pubmed/37894379 http://dx.doi.org/10.3390/cancers15205012

Ejemplares similares

The effect of organ-specific tumor microenvironments on response patterns to immunotherapy
por: Conway, Jordan W., et al.
Publicado: (2022)

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
por: Attrill, Grace Heloise, et al.
Publicado: (2022)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8(TH) EDITION STAGE III MELANOMA PATIENTS
por: Haydu, Lauren, et al.
Publicado: (2019)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
por: Nahar, Kazi J, et al.
Publicado: (2020)

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
por: Conway, Jordan W, et al.
Publicado: (2022)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Causes, consequences and clinical significance of aneuploidy across melanoma subtypes
por: Shteinman, Eva R., et al.
Publicado: (2022)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach
por: Mao, Yizhe, et al.
Publicado: (2023)

Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
por: Lawless, Anna K., et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Induced Pericarditis and Encephalitis in a Patient Treated With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report and Review of the Literature
por: Braden, Jorja, et al.
Publicado: (2021)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
por: Pupo, Gulietta M., et al.
Publicado: (2017)

Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors
por: Muir, Christopher Alan, et al.
Publicado: (2021)

The Prediction of Survival after Surgical Management of Bone Metastases of the Extremities—A Comparison of Prognostic Models
por: Ben Gal, Ofir, et al.
Publicado: (2022)

Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes
por: Shek, Dmitrii, et al.
Publicado: (2021)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
por: Gide, Tuba N., et al.
Publicado: (2021)

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
por: Gide, Tuba N., et al.
Publicado: (2019)

Comprehensive analysis of cutaneous and uveal melanoma liver metastases
por: Hoefsmit, Esmee P, et al.
Publicado: (2020)

Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review
por: Araujo, Raphael L C, et al.
Publicado: (2017)

Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors
por: Ziemys, Arturas, et al.
Publicado: (2020)

Neutrophil-to-lymphocyte ratio as a prognostic factor for survival in patients with colorectal liver metastases: A systematic review
por: Papakonstantinou, Menelaos, et al.
Publicado: (2022)

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2022)

Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
por: Lee, Hansol, et al.
Publicado: (2021)

Response to Letter to the Editor: “Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes”
por: Tsang, Venessa H M, et al.
Publicado: (2020)

Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas
por: Silva, Inês Pires da, et al.
Publicado: (2018)

The Role of Urinary VEGF in Observational Studies of BPS/IC Patients: A Systematic Review
por: Abreu-Mendes, Pedro, et al.
Publicado: (2022)

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
por: Lee, J H, et al.
Publicado: (2019)

Correlation between the expression of vegf and survival in osteosarcoma
por: Baptista, André Mathias, et al.
Publicado: (2014)

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients
por: Lim, Su Yin, et al.
Publicado: (2017)

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2020)

Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition
por: Park, John J., et al.
Publicado: (2021)

Value of Artificial Intelligence in Evaluating Lymph Node Metastases
por: Caldonazzi, Nicolò, et al.
Publicado: (2023)

Electrochemotherapy in the Treatment of Bone Metastases: A Systematic Review
por: Bocchi, Maria Beatrice, et al.
Publicado: (2023)

SLT-VEGF Reduces Lung Metastases, Decreases Tumor Recurrence, and Improves Survival in an Orthotopic Melanoma Model
por: Ackerman, Rachel, et al.
Publicado: (2010)

Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis
por: Nahar, Kazi J., et al.
Publicado: (2022)

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors
por: Lezcano, Cecilia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fsk6v6d0342805j18j1ocdh70e